The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
S1900E: A phase II study examining impact of co-mutations on sotorasib for previously treated stage IV/recurrent KRAS G12C mutated (MUT) non-squamous (Non-sq) non-small cell lung cancer (NSCLC) (ECOG-ACRIN led Lung-MAP Sub-study).
 
Sukhmani Padda
Honoraria - CME Solutions; Curio Science; Janssen; Jazz Pharmaceuticals; MECC Global Meetings; Medical Oncology Association of Southern California; Medical Oncology Association of Southern California; MJH Healthcare Holdings, LLC; Nanobiotix; OncLive/MJH Life Sciences; Physicans' Education Resource; The New England Journal of Medicine
Consulting or Advisory Role - Amgen; Amgen; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Blueprint Medicines; BMS GmbH & Co. KG; G1 Therapeutics; Genentech; Genzyme; Janssen Oncology; Janssen Oncology; Jazz Pharmaceuticals; Lilly; Mirati Therapeutics; Mirati Therapeutics; RayzeBio; Regeneron; Regeneron; Sanofi; Summit Therapeutics; Takeda; Takeda
Research Funding - Amgen (Inst); BioAtla (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Regeneron
Other Relationship - NIH/NCI; OncLive/MJH Life Sciences
 
Mary Redman
No Relationships to Disclose
 
David Gerber
Stock and Other Ownership Interests - Gilead Sciences; Walgreens
Consulting or Advisory Role - Catalyst Pharmaceuticals; Daichi Sankyo; Elevation Oncology; Janssen Oncology; Jazz Pharmaceuticals; Regeneron; Sanofi
Research Funding - AstraZeneca (Inst); BerGenBio (Inst); Karyopharm Therapeutics (Inst); Novocure (Inst)
Patents, Royalties, Other Intellectual Property - Co-founder, Chief Scientific Officer, OncoSeer Diagnostics, LLC; Royalties from Decision Support in Medicine from the Clinical Decision Support--Oncology on-line program.; Royalties from Oxford University Press from two books.; UTSD 3352 - US Patent Application 17/045,482 PREDICTION AND TREATMENT OF IMMUNOTHERAPEUTIC TOXICITY (“Chemokines” and “Cytokines”); UTSD 3352 - US Patent Application 17/045,482 PREDICTION AND TREATMENT OF IMMUNOTHERAPEUTIC TOXICITY (“Chemokines” and “Cytokines”); UTSD 4153 - US Patent Application 63/386,387 IMMUNOTHERAPY TOXICITY – CELL PHENOTYPES; UTSD 4169 - US Patent Application 63/382,972 BIOMARKERS INCLUDING RNA FOR IMMUNOTHERAPY TOXICITY; UTSD 4169 - US Patent Application 63/382,972 BIOMARKERS INCLUDING RNA FOR IMMUNOTHERAPY TOXICITY; UTSD 4184 - US Patent Application 63/382,257 T CELL TOLERANT FRACTION AS A PREDICTOR OF IMMUNE-RELATED ADVERSE EVENTS; UTSD 4184 - US Patent Application 63/382,257 T CELL TOLERANT FRACTION AS A PREDICTOR OF IMMUNE-RELATED ADVERSE EVENTS; UTSD 4287 – US Patent Application TBD INNATE AND ADAPTIVE IMMUNE FEATURES ASSOCIATED WITH TOXICITIES IN PATIENTS RECEIVING CHECKPOINT INHIBITOR THERAPY
Other Relationship - OncoSeer Diagnostics
(OPTIONAL) Uncompensated Relationships - Bristol-Myers Squibb
 
Katherine Minichiello
No Relationships to Disclose
 
Dhaval Mehta
Stock and Other Ownership Interests - Abbvie; Lilly
Honoraria - Cardinal Health; Curio Science; IntegraConnect
Consulting or Advisory Role - AstraZeneca; BeiGene
 
Sandeep Mashru
No Relationships to Disclose
 
Hosam Hakim
No Relationships to Disclose
 
Julie Brahmer
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Genmab; GlaxoSmithKline; Janssen Oncology; Mestag Therapeutics; RAPT Therapeutics; Sanofi; Summit Therapeutics
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst)
Other Relationship - Bristol-Myers Squibb; Merck; Regeneron
 
Jeffrey Bradley
Honoraria - Mevion Medical Systems
Consulting or Advisory Role - Genentech; Varian Medical Systems
Research Funding - Varian Medical Systems (Inst)
 
Tom Stinchcombe
Consulting or Advisory Role - Abbvie; Boehringer Ingelheim; Coherus Biosciences; Gilead Sciences; Janssen Oncology; Pfizer; Takeda
Research Funding - Boehringer Ingelheim (Inst); Mirati Therapeutics (Inst); Nuvalent, Inc. (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Pfizer
Other Relationship - Genentech; GlaxoSmithKline; Merck; Seagen
 
Jhanelle Gray
Honoraria - AstraZeneca; Blueprint Medicies; Daiichi Sankyo, Inc; EMD Serono/Merck; Flatiron Health; Gilead Sciences; Gilead Sciences; IDEOlogy Health; Janssen Scientific Affairs; Jazz Pharmaceuticals; Loxo; Merck; Merck; Novartis; OncoCyte; Pfizer; Regeneron; Spectrum ODAC; Takeda; Triptych Health Partners
Consulting or Advisory Role - Abbvie; AstraZeneca; Blueprint Meicines; Daiichi Sankyo/UCB Japan; EMD Serono-Merck KGaA; Flatiron Health; Gilead Sciences; IDEOlogy Health; Janssen Scientific Affairs; Jazz Pharmaceuticals; Loxo; Merck; Novartis; OncoCyte Biotechnology Company; Pfizer; Regeneron; Spectrum Pharmaceuticals; Takeda; Triptych Health Partners
Research Funding - Array BioPharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech (Inst); Gilead Services (Inst); Lilly (Inst); Ludwig Institute for Cancer Research (Inst); Merck (Inst); Novartis (Inst); Panbela Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Abbvie; OncoCyte; Spectrum Pharmaceuticals
 
Karen Kelly
Patents, Royalties, Other Intellectual Property - Author Royalties for UpToDate, an evidence based, peer reviewed information resource, available via the web, desktop, and PDA.
 
David Kozono
Consulting or Advisory Role - Genentech
 
Karen Reckamp
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Lilly; Genentech; GlaxoSmithKline; Janssen Oncology; Merus; Novartis; Novocare; Pfizer
Research Funding - Blueprint Medicines; Daiichi Sankyo/Astra Zeneca (Inst); Elevation Oncology (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst)
 
Martin Edelman
Stock and Other Ownership Interests - Biomarker Strategies; Creatv MicroTech
Consulting or Advisory Role - BioAtla; Coherus Biosciences; GE Healthcare; Omega Therapeutics
Patents, Royalties, Other Intellectual Property - Patent application for radiopharmaceutical to treat small cell lung cancer. (Inst)
Other Relationship - Anheart Therapeutics; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Seagen; Takeda
 
Hossein Borghaei
Stock and Other Ownership Interests - Nucleai; Rgenix; Sonnet
Honoraria - Amgen; Axiom Biotechnologies; Bristol-Myers Squibb; Celgene; Daiichi Sankyo/UCB Japan; Pfizer; Regeneron
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; Bayer; Beigene; BerGenBio; BioNTech; Boehringer Ingelheim; Bristol-Myers Squibb; EMD Serono; Genentech; Genmab; Grid Therapeutics; Guardant Health; IO Biotech; ITeos Therapeutics; Janssen Oncology; Jazz Pharmaceuticals; Lilly; Merck; Mirati Therapeutics; natera; Novartis; oncocyte; Pfizer; PharmaMar; Puma Biotechnology; RAPT Therapeutics; Regeneron; Rgenix; Sonnet; Takeda
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Celgene; Clovis Oncology; EMD Serono; Genentech; Lilly; Merck; Mirati Therapeutics; Novartis; Regeneron
Other Relationship - Incyte; Novartis; SpringWorks Therapeutics; Takeda; University of Pennsylvania
 
Jyoti Patel
Consulting or Advisory Role - Abbvie; Anheart Therapeutics; AstraZeneca; Blueprint Medicines; Daiichi Sankyo/Astra Zeneca; Genentech; Gilead Sciences; Guardant Health; Sanofi; Takeda Science Foundation
Travel, Accommodations, Expenses - Tempus
 
Roy Herbst
Leadership - American Association for Cancer Research; Friends of Cancer Research; IASLC; Immunocore; Junshi Pharmaceuticals; Society for Immunotherapy of Cancer; SWOG
Stock and Other Ownership Interests - Bolt Biotherapeutics; Checkpoint Therapeutics; Immunocore; Normunity
Consulting or Advisory Role - Abbvie; Amgen; ArriVent Biopharma; AstraZeneca; Bristol-Myers Squibb; Candel Therapeutics; Catalym; Checkpoint Therapeutics; Cybrexa Therapeutics; Genentech/Roche; Gilead/Forty Seven; I-Mab; Janssen; Junshi Pharmaceuticals; Lilly; Mediflix; Merck; NEUVOGEN; NextCure; Normunity; Novartis; Pfizer; Regeneron; Roche; Sanofi
Research Funding - AstraZeneca; Genentech/Roche; Lilly; Merck
Travel, Accommodations, Expenses - American Cancer Society; IASLC; SWOG
 
Suresh Ramalingam
Research Funding - Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Abbvie
Other Relationship - American Cancer Society
 
Joel Neal
Honoraria - Biomedical Learning Institute; Clinical Care Options; CME Matters; HMP Education; Medical Educator Consortium; Medscape; MJH Life Sciences; Peerview; Prime Oncology; Projects in Knowledge; Research to Practice; Rockpointe CME
Consulting or Advisory Role - Abbvie; Amgen; Anheart Therapeutics; AstraZeneca; Blueprint Medicines; Bristol-Myers Squibb; D2G Oncology; Daiichi Sankyo/Astra Zeneca; Exelixis; Genentech/Roche; Gilead Sciences; Iovance Biotherapeutics; Janssen Oncology; Lilly; Mirati Therapeutics; Natera; Novartis; Novocure; Nuvation Bio; Regeneron; Sanofi/Regeneron; Summit Therapeutics; Surface Oncology; Takeda; Turning Point Therapeutics
Research Funding - AbbVie (Inst); Adaptimmune (Inst); Boehringer Ingelheim (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Novocure (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Up To Date - Royalties